Detalles de la búsqueda
1.
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Lancet
; 401(10383): 1159-1171, 2023 04 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36871574
2.
Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events From the ELEVATE UC Clinical Program.
J Crohns Colitis
; 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38700040
3.
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
J Crohns Colitis
; 2024 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38877972
4.
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
J Crohns Colitis
; 2024 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38613425
5.
Efficacy and Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.
J Crohns Colitis
; 2023 Dec 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38096402
6.
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II.
J Crohns Colitis
; 15(6): 938-949, 2021 Jun 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33599720
Resultados
1 -
6
de 6
1
Próxima >
>>